Sign In
Buy CLVLY
$6.40
-0.0800 (-1.23%)
At Close: Jun 03, 2026
Clinuvel Pharmaceuticals Limited (CLVLY) Q2 2023 Earnings Call Transcript
01:12am, Friday, 23'rd Feb 2024
Clinuvel Pharmaceuticals Limited (CLVLY) Q2 2023 Earnings Call Transcript
Clinuvel Pharmaceuticals Limited (CLVLY) Q2 2022 Results - Earnings Call Transcript
04:20pm, Thursday, 24'th Feb 2022
Clinuvel Pharmaceuticals Limited (CLVLY) Q2 2022 Results - Earnings Call Transcript
CLINUVEL expands DNA Repair Program
08:10pm, Tuesday, 23'rd Mar 2021
SCENESSE® (afamelanotide 16mg) to be evaluated in xeroderma pigmentosum variant (XP-V)
Clinuvel publishes its long-awaited Strategic update
04:20pm, Friday, 06'th Nov 2020
Clinuvel Pharmaceutical has introduced its first commercial product “Scenesse” in Europe and the US in 2014 and 2019 for the rare disease “EPP”. Since then, it has stayed very secretive about
